pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,636 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: The hunt for FDA’s next leader
    Marty Makary is out, and the Trump administration has a long wish list for its next FDA commissioner.
    STAT · 2mo ago↗ source
  • STAT+: MIT says research has fallen 10%, and grad student enrollment is down
    At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.
    STAT · 2mo ago↗ source
  • Drugmakers have to go through rigorous tests to get a lower tariff rate
    Landing a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive or…
    Endpoints · 2mo ago↗ source
← prev
page 50 of 66
next →
22
fda press21
fda medwatch17
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
    💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…
    Endpoints · 2mo ago↗ source
  • AstraZeneca follows Merck with Phase 3 win in bladder cancer
    A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…
    Endpoints · 2mo ago↗ source
  • STAT+: BeOne wins FDA approval in lymphoma race
    Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • MacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack
    Plus, news about Bavarian Nordic and OrganaBio’s new CDMO subsidiary: 🏭 Bora buys MacroGenics' manufacturing operations: MacroGenics is selling its clinical and commercial drug substance productio…
    Endpoints · 2mo ago↗ source
  • STAT+: Why big digital health players are missing from Medicare’s chronic care experiment
    In this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
    Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau
    STAT · 2mo ago↗ source
  • How Penn Medicine plans to use AI to train their doctors
    Physicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...
    Endpoints · 2mo ago↗ source
  • STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns
    The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy
    Here we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at…
    Endpoints · 2mo ago↗ source
  • STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
    Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
    STAT · 2mo ago↗ source
  • Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval
    Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to com…
    Endpoints · 2mo ago↗ source
  • STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
    CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
    STAT · 2mo ago↗ source
  • STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
    Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
    STAT · 2mo ago↗ source
  • BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
    BeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…
    Endpoints · 2mo ago↗ source
  • STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
    Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the agency.
    STAT · 2mo ago↗ source
  • STAT+: Treatment for alcohol addiction is undergoing a seismic shift. Many say it’s overdue
    The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape. Many say it's overdue.
    STAT · 2mo ago↗ source
  • Opinion: Using AI in addiction medicine could be particularly risky
    "AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," writes Steve D. Klein.
    STAT · 2mo ago↗ source
  • Hantavirus risk remains low, CDC says, citing its ‘playbook’ response
    Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low.
    STAT · 2mo ago↗ source
  • Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud
    Vice President JD Vance announced a $1.3 billion deferral in Medicaid reimbursements to California, as part of an initiative to root out fraud in federal health programs.
    STAT · 2mo ago↗ source
  • Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?
    Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in one while being treated for Ebola, watching the news…
    STAT · 2mo ago↗ source
  • #ASGCT26: After an apparent cure, a gene editing company struggles to repeat the magic
    BOSTON — Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new results testing the same therapy in a larger number of bab…
    Endpoints · 2mo ago↗ source
  • Takeda to target 4,500 jobs as incoming CEO continues restructuring
    Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring. About 4,500 roles will be affected, the company said Wednesday in ...
    Endpoints · 2mo ago↗ source